Consolidated Financial Statements for the Third Quarter Ended December 31, 2018
FY2019 (April 1, 2018 - March 31, 2019) [UNAUDITED]Company name:
Stock exchange listings:
Code number:
URL:
Company representative:
Contact:

January 30, 2019
Takara Bio Inc.
Tokyo Stock Exchange (1st section)4974
http://www.takarabio.com/
Koichi Nakao, President
Shuichiro Matsuzaki, Executive Vice President
Tel. (077) 565-6970
February 8, 2019

Quarterly statement filing date (as planned)
Scheduled date of starting delivery of dividends:
Supplementary documents of the financial results
YesFinancial results information meeting:
NoNotes: 1. The accompanying financial statements have been prepared in accordance with accounting principles andpractices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.
1. Results for the nine months ended December 31, 2018 (Apr. 1, 2018 – Dec. 31, 2018)(1) Operating results(Percentages indicate changes from the same period of the previous fiscal year.)Nine months ended
Dec. 31, 2018
Net sales
Operating income
Ordinary income
Net income (loss) attributable to owners of theparent
Net income per share (in yen)
Fully diluted net income per share (in yen)
Note: Comprehensive income(Millions of yen)
25,888
3,432
3,549
2,088

Nine months ended
Dec. 31, 2017
(%)
14.3
113.4
101.4
95.4

17.35
1,776

(Millions of yen)
22,646
1,608
1,762
1,068

(%)
9.7
(41.0)(38.6)(31.5)

8.88(118.8%)811(%)(2) Financial position
As of Dec. 31, 2018
(Millions of yen)

As of Mar. 31, 2018
(Millions of yen)

Total assets
70,70568,670Net assets
63,193
61,959Equity ratio (%)
89.2
90.1
Net assets per share (in yen)523.97513.66(Reference) Equity
63,09461,852
Notes: Partial revision of accounting standard related to tax effect accounting (Article 28 on corporate accounting standard,February 16, 2018) has been applied from the beginning of the year ending March 31, 2019. Accordingly, financial
position for the year ended March 31, 2018 indicates the numerical value after retroactive adjustment due to this revision.

2. Dividends
Annual dividends per share in yen
Year ended Mar. 31,
Year ending Mar. 31,
Year ending Mar. 31,201820192019 (Forecast)First quarter end
Second quarter end
0.00
0.00
Third quarter end
Year end
4.50
Annual4.50
Note: Revision of dividend payment forecast since the most recently announced payment forecast ： Yes

7.00
7.00

3. Forecast for the year ending March 31, 2019 (Apr. 1, 2018 – Mar. 31, 2019)(Percentages indicated changes from the same period of the previous fiscal year.)Year ending Mar. 31, 2019
(Millions of yen)(%)
Net sales
35,800Operating income
5,200
Ordinary income
5,400
Net income attributable to owners of the3,150
parent
Net income per share (in yen)
26.16
Note: Revision of financial forecast since the most recently announced financial forecast ： Yes

10.8
46.2
39.8
34.9

※ Others(1) Changes in subsidiaries during the nine months ended Dec. 31, 2018
(Changes in specified subsidiaries resulting in change of scope) ： No
Newly included: (Name)
Excluded: (Name)(2) Application of special accounting methods to the consolidated quarterly financial statements： No(3) Changes in accounting policies, changes in accounting estimates, and retrospective restatement①Changes based on revisions of accounting standard： No②Changes other than ones based on revisions of accounting standard： No③Changes in accounting estimates： No④Restatement： No(4) Number of outstanding shares (Common stock)① Number of outstanding shares at year end (Treasury stocks are included)
120,415,600
As of December 31, 2018
As of March 31, 2018
120,415,600② Number of treasury stocks at year end
As of December 31, 2018
As of March 31, 2018
③ Average number of outstanding shares (Quarterly total)
120,415,600
As of December 31, 2018
120,415,600
As of December 31, 2017
※ These quarterly financial statements are not subject to auditing.
※ Comment regarding appropriate use of earnings forecasts and other special notes
Forward-looking statements contained in this document are determined by the Takara Bio based on information
currently available to the Company and include a number of uncertainties. Actual results could differ from these
forecasts due to changes in conditions that occur in the future. For information regarding the above, please refer to“1. Qualitative Information for the nine months ended December 31, 2018 (4) Qualitative Information Regarding
Consolidated Forecasts, on page 3 of the attached document”.
(Change in calendar indication)
Calendar indication has been changed from Japanese style to western style since Consolidated Financial
Statements for the first quarter ended June 30, 2018.